Therapeutic Inertia in Prescribing Biologics for Patients with Moderate-to-Severe Asthma: Workshop Summary.

Sico, Isabelle P

Oberle, Amber

Thomas, Sheila M

Barsanti, Thomas

Egbuonu-Davis, Lisa

Kennedy, Daniel T

Zullig, Leah L

Bosworth, Hayden B

2022-08-01T13:17:46Z

2022-08-01T13:17:46Z

2021-01

2022-08-01T13:17:45Z

Moderate-to-severe asthma represents about a quarter of the nearly 10% of Americans diagnosed with asthma. Many patients with moderate-to-severe asthma have uncontrolled symptoms that lead to exacerbations requiring oral corticosteroids. There are many factors contributing to poor asthma control, including poor adherence to prescribed therapies, the under-prescribing of biologics and therapeutic inertia. We convened an eight-member panel from fields of primary care, pulmonology, immunology, health services and clinical research, behavioral science and pharmaceutical medical affairs, with the goal of identifying contributing factors and solutions to therapeutic inertia with asthma biologics. We used the Capability, Opportunity, and Motivation (COM-B) model to classify patient and provider behavior towards therapeutic inertia. The model incorporates existing behavior theories and is driven by the interaction of capability, opportunity, and motivation. We used a Delphi method to identify and develop six primary solutions: 1) integration of patient-centered outcomes into asthma management practice; 2) provider education about asthma treatment; 3) moderate-to-severe asthma care delivery redesign; 4) harmonized, evidence-based protocol for the management of moderate-to-severe asthma; 5) designated coordinator approach for optimal asthma management; and 6) a case coordination digital support tool. Integration of patient-centered outcomes into asthma management practice and provider education were identified as having the highest potential to impact therapeutic and clinical inertia. The COM-B model is effective in identifying improvement within therapeutic inertia targeting the capabilities, opportunities, and motivations of patients, providers, and payer systems.

303841

1177-889X

1177-889X

https://hdl.handle.net/10161/25532

eng

Informa UK Limited

Patient preference and adherence

10.2147/ppa.s303841

COM-B

asthma

clinical inertia

therapeutic inertia

Therapeutic Inertia in Prescribing Biologics for Patients with Moderate-to-Severe Asthma: Workshop Summary.

Journal article

Zullig, Leah L|0000-0002-6638-409X

Bosworth, Hayden B|0000-0001-6188-9825

705

712

Duke

Fuqua School of Business

School of Medicine

Staff

Basic Science Departments

Clinical Science Departments

Institutes and Centers

Family Medicine and Community Health

Medicine

Psychiatry & Behavioral Sciences

Medicine, General Internal Medicine

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Duke Cancer Institute

Institutes and Provost's Academic Units

University Institutes and Centers

Center for the Study of Aging and Human Development

Initiatives

Duke Science & Society

Population Health Sciences

Duke Innovation & Entrepreneurship

Duke - Margolis Center for Health Policy

Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences

Innovation & Entrepreneurship Initiative

Published

15